We are live on
!
Find out more
AG
Artal Group Portfolio holdings
AUM
$1.01B
1-Year Est. Return
29.84%
This Fund
S&P 500
This Quarter
Est. Return
-4.61%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.5B
AUM Growth
-$546M
(-11%)
Cap. Flow
-$309M
Cap. Flow
% of AUM
-6.85%
Top 10 Holdings %
Top 10 Hldgs %
82.03%
Holding
109
New
17
Increased
29
Reduced
12
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$24.5M |
| 2 |
ATH
Athene Holding Ltd. Class A Common Shares
ATH
|
+$18.5M |
| 3 |
Agios Pharmaceuticals
AGIO
|
+$18.4M |
| 4 |
ZTO Express
ZTO
|
+$14.4M |
| 5 |
CELG
Celgene Corp
CELG
|
+$11.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Goldman Sachs
GS
|
+$32.3M |
| 2 |
Bank of America
BAC
|
+$19.3M |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
+$16.6M |
| 4 |
Morgan Stanley
MS
|
+$13.2M |
| 5 |
Aptiv
APTV
|
+$10.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Staples | 46.77% |
| 2 | Healthcare | 25.98% |
| 3 | Consumer Discretionary | 7.97% |
| 4 | Financials | 0.43% |
| 5 | Industrials | 0.27% |
Similar funds
BCM
GA
EPAM
WA
CT
AH
PIM
MAM
Artal Group's Q4 2016 Portfolio in Review
As of Q4 2016, Artal Group held 109 positions worth $4.5B, down 11% from $5.05B the previous quarter. Its ten largest holdings account for 82% of the portfolio.
Artal Group withdrew a net $309M in Q4 2016, closing 18 positions and reducing 12 holdings. Its most notable exit was Goldman Sachs, an estimated $32.3M position sold in full.
By sector, the portfolio is most concentrated in Consumer Staples at 47% of assets, up from 41% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Artal Group opened a new position in Alexion Pharmaceuticals worth $24.5M.
- Artal Group's largest Q4 2016 buy was Alexion Pharmaceuticals: 200,000 shares worth $24.5M.
- Artal Group added most to Agios Pharmaceuticals in Q4 2016, an estimated $18.4M increase.
- Artal Group's biggest Q4 2016 reduction was Array Biopharma Inc, cutting an estimated $16.6M.
- Artal Group fully exited Goldman Sachs in Q4 2016, selling an estimated $32.3M.
- Artal Group's ten largest holdings make up 82% of its $4.5B portfolio in Q4 2016.
- Artal Group opened 17 new positions and closed 18 in Q4 2016.
- Artal Group's portfolio value fell 11% quarter-over-quarter to $4.5B.
Based on Artal Group's 13F filing for Q4 2016, filed 14 Feb 2017.